Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
The role of cytochrome P450 (CYP)2C9 and CYP2C19 genetic variation in risk for phenytoin‐induced cutaneous adverse drug events is not well understood independently of the human leukocyte antigen B (HLA‐B)*15:02 risk allele. In the multi‐ethnic resource for Genetic Epidemiology Research on Adult Heal...
Saved in:
Main Authors: | Alison E. Fohner (Author), Allan E. Rettie (Author), Khanh K. Thai (Author), Dilrini K. Ranatunga (Author), Brian L. Lawson (Author), Vincent X. Liu (Author), Catherine A. Schaefer (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
by: Nizamuddin S, et al.
Published: (2021) -
CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment
by: Silvado CE, et al.
Published: (2018) -
The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
by: Ping Siu Kee, et al.
Published: (2023) -
Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects
by: Natalia Guevara, et al.
Published: (2017) -
VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
by: Lindsay M. Henderson, et al.
Published: (2019)